Nuclera (NUCLERA NUCLEICS LTD.)

Company Snapshot

Founded: 2013
Entity Type: Private
Region: U.K.
Headquarter: Cambridge, U.K.
Key Geographics: U.K., U.S.
Corporate Address: One Vision Park, Station Road, Impington, Cambridge, CB24 9NP U.K. Tel: +44-1223-625095 www.nuclera.com

Company Overview

Nuclera Nucleics is developing next-generation DNA synthesis technology based on proprietary engineered enzymes. The enzymes, terminal deoxynucleotidyl transferases (TdT) allow production of genes and genome libraries. Nuclera’s goal is to make synthetic DNA accessible to small- and mid-sized laboratories.

Recently Nuclera raised $15.5 million in additional funding in a Series B financing round totaling up to $58 million. The company has raised a total of $83.3 million to develop its proprietary DNA synthesis technology. The additional investments will be used to accelerate the commercial launch of the eProtein desktop bioprinter.

Nuclera (NUCLERA NUCLEICS LTD.) In Reports

DNA Data Storage: Global Markets and Technologies

BCC Research Market Report for DNA Data Storage technologies reach $1.5 bln by 2027 from $105.5 mln in 2022 at CAGR of 69.8% for the period of 2022 to 2027.

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

DNA Data Storage: Global Markets and Technologies

BCC research global markets report for DNA data storage. market trends, with data from 2019, estimates for 2020, and projections of CAGRs through 2025.

Company's Business Segments

  • Products : Instrument, Cartridge, Reagents, Software, Others
  • Services : eProtein Discovery System, Others

Applications/End User Industries

  • Biotechnology
  • Healthcare
  • Pharmaceuticals
  • Research and Academics
  • Life Sciences
AI Sentiment